Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04480216
Other study ID # P2019/643
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 19, 2020
Est. completion date September 15, 2021

Study information

Verified date December 2021
Source Erasme University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A novel magnetic device, called MAgnetic Gastrointestinal Universal Septotome (MAGUS) was designed to improve the Treatment of diverticulum of the esophagus, Pseudo-diverticulum of the upper GI tract, Candy cane syndrome This study aims to evaluating the safety of the feasability of this new device.


Description:

In this study, the investigators aim at treating different pathological conditions, resulting in the appearance of a septum separating a healthy pathway and a pathological pouch. Food then stagnate in this pouch and results in different symptoms including dysphagia, pain and/or regurgitation or postprandial dysrhythmia. Esophageal diverticula consists in the apparition of a pouch (diverticulum) alongside the esophagus. Some post-surgical conditions can result in the appearance of pseudo-diverticulum or afferent limb that transforms into a large pouch. One example is the candy cane syndrome, being an afferent loop syndrome post gastrectomy or post Roux-en-Y Gastric Bypass, were the afferent limb becomes a structure similar to a large diverticulum. All those pathological conditions could be solved by the marsupialization of those (pseudo-)diverticulum. For several years, Zenker's diverticula (pharyngo-esophageal diverticulum) have been treated endoscopically using this technique, providing good clinical results. However, it is difficult to go further than the pharynx with this technique, since it needs specific semi-rigid tools and a stable cutting position. Hence, for further septa of the GI tract, the classic treatment is thoracoscopy and thoracotomy or laparoscopy and laparotomy, depending on the site. Those highly invasive procedures have a significant mortality and morbidity rate respectively of more than 5% and 20% and are liked to different complications including abdominal pain, port site wound infections, intraabdominal collection or anastomosis ulcer. The MAGUS device consists of a flexible catheter preloaded with a magnetic device, made of two magnets linked by a wire. Each magnet is attached to the catheter and can be dropped separately from this catheter. The magnetic device aims to create an anastomosis by means of compression, using magnetic force and a retractable wire pulling system. For a given septum, the magnets are placed on either sides of the bottom of it. The retractable wire goes then from one another, passing on top of the septum. Both creates compression necrosis. This process induces eventually a cutting of the septum. Once the cutting is performed, the magnets migrate and are expelled through natural ways. The MAGUS device is an endoscopic procedure. Above standard of care monitoring, safety assessment of the procedure and device performance decreases the risk and unforeseen events.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date September 15, 2021
Est. primary completion date September 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years or older. - Patient has got evaluable symptoms (dysphagia, regurgitation, pain, weight loss, halitosis or others) associated with one of the following pathology: 1. Diverticulum of the esophagus; 2. A pseudo-diverticulum of the upper GI tract; 3. Candy cane syndrome; - Willing and able to comply with the study procedures and provide written informed consent to participate in the study. Exclusion Criteria: - Refractory stenosis of the UGI proximal to the septum; - Septum height smaller than 2,5 cm or higher than 6 cm (check through CT scan, Barium Swallow or other imaging method); - Coagulation disorders; - Previous implantation of a magnetic-sensitive medical device (including active electronic implant, metallic stent, …); - Dysphagia related to motility disorder; - Planned MRI in the following month (30 days) of intervention. - Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety; - Patient went through a surgery less than 8 weeks before implantation of the magnets; - Currently enrolled in another clinical trial.

Study Design


Intervention

Device:
MAGUS
An upper endoscopy will be performed with the use of fluoroscopy. The MAGUS will be placed under fluoroscopy. The good positioning and the absence of any complications will be confirmed by gastroscopy. An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened. The patient will be kept overnight, with liquid food for 2 and mashed food up to 7 days post procedure

Locations

Country Name City State
Belgium Hopital Erasme Bruxelles

Sponsors (1)

Lead Sponsor Collaborator
Erasme University Hospital

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Technical magnet placement success ability to deploy the MAGUS in satisfactory position across the septum (YES/NO) Day 0
Primary Type of evacuation of the device natural or endoscopic During 28 Days post-placement
Primary Incidence of all adverse event SAE during device placement During 30 days post-placement
Secondary Number and type of AE after placement During 3 month post placement
Secondary Patient's report of pain: visual analog scale scored by a visual analog scale from 0 to 10 (0=no pain) Before treatment - Day 1 - Day 14 - Day 28 - Month 3
Secondary Number of unplanified interventions During 3 months post-placement
Secondary Change of Eckardt and dysphagia score or GERD HRQL score Before treatment - Day 1 - Day 14 - Day 28 - Month 3
Secondary Patient's satisfaction with the therapy: visual analogue scale scored by a visual analogue scale from 0 to 10 (10= fully satisfied) Day 14 - Day 28 - Month 3
Secondary Emptying rate of the diverticular structure Month 3
Secondary Difference of height of the septum cut before and after the treatment Month 3
Secondary Change of SF12 quality of life score Before treatment - Month 3
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04514042 - Comparison of Zenker's Diverticulum Treatment Using Peroral Endoscopic Myotomy and Flexible Endoscopy Septotomy. N/A